

## Table of Contents

<b>1. ABSTRACT OF SCIENTIFIC RESULTS.....</b>	<b>7</b>
<b>2. ZUSAMMENFASSUNG DER WISSENSCHAFTLICHEN ERGEBNISSE .....</b>	<b>9</b>
<b>3. GENERAL INTRODUCTION TO COMMON CARDIOVASCULAR DISEASES .</b>	<b>11</b>
3.1. Overview of the most common forms of cardiovascular disease.....	11
3.2 Epidemiology of cardiovascular diseases.....	11
3.2.1 Mortality and morbidity of cardiovascular diseases .....	11
3.2.2 The process of epidemiologic transition .....	13
3.3. Risk factors of cardiovascular disease .....	15
3.3.1 High Blood Pressure.....	15
3.3.2 Diabetes mellitus.....	17
3.3.3. Dyslipidemia and hypercholesterolemia.....	20
3.3.4 Smoking.....	21
3.3.5. Overweight and obesity.....	23
3.3.6. Physical inactivity.....	25
3.3.7 Nutrition.....	27
<b>4. MICROARRAY GENE EXPRESSION PROFILING REVEALS ANTIOXIDANT- LIKE EFFECTS OF ANGIOTENSIN II INHIBITION IN ATHEROSCLEROSIS .</b>	<b>31</b>
4.1. Introduction into atherosclerosis and Coronary Artery Disease (CAD).....	31
4.1.1 Pathomechanisms of atherosclerosis and Coronary Artery Disease.....	31
4.1.1.1 Stages of atherosclerosis .....	31
4.1.1.2 Keyplayers of atherosclerosis.....	31
4.1.1.3 Role of the innate immune system in atherosclerosis.....	34
4.1.1.3.1 Monocytes.....	34
4.1.1.3.2 Complement .....	36
4.1.1.4 Adaptive immunity and atherosclerosis.....	38
4.1.1.4.1 Effects of T lymphocytes in atherosclerosis.....	38
4.1.1.4.2 The role of B cells in atherosclerosis .....	44
4.1.1.5 The role of the Renin Angiotensin Aldosterone System in atherosclerosis .....	46
4.1.2 Diagnosis of stable Coronary Artery Disease.....	49
4.1.2.1 Patient history and physical examination .....	49
4.1.2.2 Resting ECG .....	49
4.1.2.3 Probability estimate .....	49
4.1.2.4 Noninvasive Testing for Diagnosis of CHD – Functional Testing.....	50
4.1.2.5 The ischemic cascade .....	51
4.1.3 Treatment of risk factors for Coronary Artery Disease .....	52
4.1.3.3 Blood pressure management .....	54
4.1.3.4 Diabetes management .....	55
4.1.4 Pharmacotherapy of atherosclerosis.....	56
4.1.4.1 Statins.....	56
4.1.4.2 Use of ACE Inhibitors and ARBs in atherosclerosis.....	59
4.1.5 Emerging approaches for the treatment of hypercholesterinemia and atherosclerosis .....	62
4.1.5.1 PCSK9 Inhibitors.....	62
4.1.5.2 PCSK9 inhibitors approved for clinical use .....	62

4.1.5.3 Microsomal triglyceride Transfer protein (MTTP) inhibitor.....	63
4.1.5.4 Antisense oligonucleotide Mipomersen.....	63
4.1.5.4 Novel HDL-targeted therapy approaches.....	63
4.2. Scientific goal of PhD research project “Microarray gene expression profiling reveals antioxidant-like effects of angiotensin II inhibition in atherosclerosis”.....	65
4.3. Publication “Microarray gene expression profiling reveals antioxidant-like effects of angiotensin II inhibition in atherosclerosis”.....	66
4.3.1 Abstract.....	66
4.3.2 Introduction.....	67
4.3.3 Materials and Methods.....	68
4.3.3.1 Atherosclerosis treatment of ApoE <sup>-/-</sup> mice.....	68
4.3.3.2 Whole genome microarray gene expression profiling.....	68
4.3.3.3 Histology analyses and immunodetection of proteins.....	68
4.3.4 Results.....	69
4.3.4.1 Angiotensin-converting enzyme inhibition by captopril or antioxidant treatment with vitamin E retarded the formation of atherosclerotic lesions in ApoE <sup>-/-</sup> mice.....	69
4.3.4.2 ACE inhibition by captopril and vitamin E treatment prevented the increase in aortic superoxide content of ApoE <sup>-/-</sup> mice.....	71
4.3.4.3 Whole genome microarray gene expression profiling of atherosclerosis treatment with vitamin E and captopril revealed concordantly regulated aortic genes.....	71
4.3.4.4 Vitamin E and ACE inhibitor treatment maintained the integrity of aortic intima genes of atherosclerosis-prone ApoE <sup>-/-</sup> mice.....	74
4.3.4.5 Antioxidant and ACE inhibitor treatment preserved the contractile phenotype of aortic media.....	75
4.3.4.6 Pro-inflammatory immune cell recruitment into the atherosclerosis-prone aorta was sensitive to ACE inhibition but insensitive to vitamin E treatment.....	77
4.3.4.7 ACE-inhibition prevented the atherosclerosis-related down-regulation of perivascular nerve-specific genes of ApoE <sup>-/-</sup> mice.....	79
4.3.5. Discussion.....	82
<b>5. INHIBITION OF G PROTEIN-COUPLED RECEPTOR KINASE 2 PREVENTS THE DYSFUNCTIONAL CARDIAC SUBSTRATE METABOLISM IN FATTY ACID SYNTHASE-TRANSGENIC MICE.....</b>	<b>85</b>
5.1. Introduction to Heart Failure (HF).....	85
5.1.1 Epidemiological landmarks of Heart Failure.....	85
5.1.2 Definition and classification of Heart Failure.....	86
5.1.2.1 Definition of ejection fraction.....	86
5.1.2.2 Heart Failure with reduced Ejection Fraction (HFrEF).....	86
5.1.2.3 Heart failure with preserved ejection fraction (HFpEF).....	86
5.1.2.4 Asymptomatic Left Ventricular Dysfunction (LVD).....	87
5.1.3 Classification of Heart Failure.....	87
5.1.3.1 The New York Heart Association (NYHA) functional classification.....	87
5.1.3.2 The American Heart Association (AHA) classification.....	88
5.1.4 Selected Pathomechanisms of Heart Failure.....	88
5.1.4.1 Diseases and comorbidities associated with the development of Heart Failure.....	88
5.1.4.2 Cardiac metabolism and metabolic dysfunction.....	89
5.1.4.2.1 Metabolic regulation in the normal heart.....	90
5.1.4.2.1.1 Cardiac lipid metabolism.....	90
5.1.4.2.1.2 Cardiac glucose metabolism.....	91
5.1.4.2.1.3 The PPAR/ERR/PGC-1 axis.....	93
5.1.4.2.2. Metabolic dysfunction in heart failure and diabetic cardiomyopathy.....	96

5.1.4.2.2.1 Metabolic changes in the diabetic heart.....	96
5.1.4.2.2.2 Molecular mechanisms of metabolic shift in diabetic cardiomyopathy.....	98
5.1.4.2.2.2.1 Disturbed cardiac fatty acid metabolism in diabetes.....	98
5.1.4.2.2.2.2 Activation of PPAR-alpha and its target genes.....	98
5.1.4.2.2.2.3 Less efficient generation of energy equivalents (ATP) by beta oxidation.....	99
5.1.4.2.2.2.4 Increased insulin resistance and inhibition of glycolysis by fatty acids.....	100
5.1.4.2.2.2.5 Increased lipotoxicity.....	100
5.1.4.2.2.2.6 Mitochondrial dysfunction.....	101
5.1.4.2.2.2.7 Increased oxidative stress.....	102
5.1.4.3 The role of GRK2 in Heart Failure.....	102
5.1.4.3.1 GRK2 mediates exaggerated beta-adrenoceptor desensitization in Heart Failure.....	103
5.1.4.3.2 Non-canonical functions of GRK2 with relevance to heart failure.....	104
5.1.4.3.2.1 GRK2 and cardiac metabolism.....	104
5.1.4.3.2.2 GRK2 and mitochondrial dysfunction.....	105
5.1.4.3.2.3 GRK2 regulates the cellular redox state through endothelial nitric oxide synthase.....	106
5.1.5 The Diagnosis of Heart Failure.....	107
5.1.5.1 Blood Biomarkers.....	107
5.1.5.2 Imaging.....	108
5.1.6 Pharmacological therapy of heart failure with reduced ejection fraction (HFrEF).....	109
5.1.7 New drugs for the treatment of Heart Failure.....	110
5.2 Scientific goals of PhD research project “Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice”.....	117
5.3 Publication “Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice”.....	118
5.3.1 Abstract.....	118
5.3.2. Introduction.....	119
5.3.3 Experimental Procedures.....	119
5.3.3.1. Generation of transgenic mice and animal experiments.....	119
5.3.3.2 Whole genome microarray gene expression analysis.....	120
5.3.3.3 Antibodies.....	121
5.3.3.4 Immunohistology analyses and immunofluorescence.....	122
5.3.3.5 Immunoblot detection of proteins.....	122
5.3.3.6. Functional assays.....	122
5.3.3.7 Measurement of cardiomyocyte substrate metabolism.....	123
5.3.3.8 Statistical analyses.....	123
5.3.4 Results.....	124
5.3.4.1 FASN-transgenic cardiomyocytes developed a dysfunctional cardiac substrate metabolism.....	124
5.3.4.2 FASN-transgenic mice developed signs of heart failure and cardiac lipid load.....	126
5.3.4.3 Up-regulation of the heart failure-related cardiac lipid metabolic process in FASN-transgenic mice.....	128
5.3.4.4 Heart failure-related adipogenic genes triggered by FASN are Pparg targets.....	129
5.3.4.5 Down regulation of endogenous Fasn reveals a causal relationship between Fasn and Pparg activation in promoting cardiac dysfunction.....	130
5.3.4.6 GRK2 inhibition by GRKInh in FASN-transgenic mice.....	131
5.3.4.7 GRK2 inhibition by GRKInh prevents the dysfunctional cardiac energetics of FASN-transgenic cardiomyocytes.....	134
5.3.4.8 GRK2 inhibition retards the development of heart failure signs in Tg-FASN mice.....	137
5.3.4.9 GRK2 inhibition promotes ERK axis-dependent inhibition of Pparg transcriptional activity.....	139

5.3.4.10	Inhibition of Fasn lowers the cardiopototoxicity induced by serine-273 phosphorylation-deficient PPARG-S273A .....
5.3.4.11	GRK2 inhibition retards the up-regulation of the heart failure-related Ucp1 and mitochondrial uncoupling .....
5.3.4.12	Transgenic Tg-UCP1 mice developed signs of heart failure and increased mitochondrial uncoupling .....
5.3.4.13	Inhibition of Ucp1 counteracts PPARG-S273A-induced cardiopototoxicity .....
5.3.4.14	Cardioprotective GRK2 inhibition requires an intact ERK axis .....
5.3.4.15	GRK2 inhibition retards the development of heart failure signs, cardiac lipid load and Pparg target gene induction in a pressure overload-induced heart failure model.....
5.3.4.16	Down-regulation of endogenous Ucp1 retards the development of cardiac dysfunction in a pressure overload-induced heart failure model .....
5.3.4.17	Low efficacy of GRK1nh in retarding the cardiac phenotype of PPARG-S273A-transgenic mice .....
5.3.5.	Discussion .....
6.1	Discussion of thesis project-1 "Microarray gene expression profiling reveals antioxidant-like effects of angiotensin II inhibition in atherosclerosis".....
6.2	Discussion of thesis project-2 "Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice.....
7.	REFERENCES.....
8.	CURRICULUM VITAE .....
9.	LIST OF PUBLICATIONS.....
10.	ABBREVIATIONS.....